EDGAR·FLOW

Theriva Biologics, Inc. — Form 8-K

Filed November 18, 2026 · analyzed by the 8-K Agent
8-K — Neutral significance 28/100
What the filing says
Theriva Biologics filed an 8-K on November 18, 2026, reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). The filing does not disclose specific details of the matters submitted, vote counts, proposal descriptions, or outcomes—only that such matters were submitted. No dollar amounts, dates of shareholder vote, or nature of proposals are specified in the filing text provided.
Why this rating

Routine disclosure of shareholder vote submission; no material details disclosed. Scale-appropriate: Theriva ~$3.9M market cap makes most corporate actions material, but bare Item 5.07 is procedural boilerplate without outcome or substance clarity.

Extracted items
View original filing on SEC.gov ↗ TOVX · stock on Yahoo Finance ↗

See more from November 18, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.